Pombiliti Disease Interactions
There is 1 disease interaction with Pombiliti (cipaglucosidase alfa).
Hydrolytic lysosomal glycogen-specific enzymes (applies to Pombiliti) cardiac/pulmonary impairment
Major Potential Hazard, Moderate plausibility. Applicable conditions: Fluid Retention, Heart Disease
Patients with an acute underlying illness at the time of avalglucosidase alfa or cipaglucosidase alfa infusion may be at greater risk for infusion-associated reactions (IARs); compromised cardiac and respiratory function may predispose patients to a higher risk of severe complications from IARs. Antihistamines, antipyretics, and/or corticosteroids can be given before avalglucosidase alfa or cipaglucosidase alfa infusion to reduce the risk of IARs; however, IARs may still occur in pretreated patients.
Patients susceptible to fluid volume overload, or patients with acute underlying respiratory illness or compromised cardiac or respiratory function for whom fluid restriction is indicated may be at risk of serious exacerbation of their cardiac or respiratory status during avalglucosidase alfa or cipaglucosidase alfa infusion; more frequent monitoring of vitals should be performed during infusion in such patients. Some patients may require prolonged observation times.
Pombiliti drug interactions
There are 2 drug interactions with Pombiliti (cipaglucosidase alfa).
More about Pombiliti (cipaglucosidase alfa)
- Pombiliti consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: lysosomal enzymes
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.